This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Determination of the in Vitro Effects of Cationic Airway Lining Modulators (CALM) on Chronic Obstructive Pulmonary Disease (COPD) Sputum

This study has been completed.
The VA Western New York Healthcare System
Buffalo Institute For Medical Research
Information provided by:
Pulmatrix Inc. Identifier:
First received: March 25, 2010
Last updated: April 7, 2011
Last verified: April 2011
This study is intended to be an evaluation of the properties of human sputum collected from patients with COPD. It is hypothesized that cationic airway lining modulators will have beneficial effects on the rheological properties of sputum derived from patients with COPD. Approximately 10 patients with COPD will collect sputum at home for 5 days. Samples will be collected and tested in laboratory tests.

Chronic Obstructive Pulmonary Disease

Study Type: Observational
Official Title: Determination of the in Vitro Effects of CALM on COPD Sputum

Resource links provided by NLM:

Further study details as provided by Pulmatrix Inc.:

Biospecimen Retention:   None Retained
Sputum samples

Estimated Enrollment: 10
Study Start Date: April 2010
Study Completion Date: October 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   35 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Outpatient clinic setting

Inclusion Criteria:

  1. Clinical and spirometric diagnosis of COPD
  2. Smoking history of at least 10 pack yrs
  3. Sputum production of greater than 2 tablespoons per day by patient report.

Exclusion Criteria:

  1. a primary diagnosis of asthma or bronchiectasis
  2. a COPD exacerbation within 4 weeks
  3. Inability to comply with study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01096173

United States, New York
VA WNY Healthcare System
Buffalo, New York, United States, 14215
Sponsors and Collaborators
Pulmatrix Inc.
The VA Western New York Healthcare System
Buffalo Institute For Medical Research
Principal Investigator: Sanjay Sethi, MD Va Western NY Healthcare, Buffalo Institute for Medical Research
  More Information

Responsible Party: Dr. Sanjay Sethi, MD, VA of Western NY Healthcare System, Buffalo Institute for Medical Research Identifier: NCT01096173     History of Changes
Other Study ID Numbers: PUL_VABUF_01
Study First Received: March 25, 2010
Last Updated: April 7, 2011

Keywords provided by Pulmatrix Inc.:
chronic obstructive pulmonary disease

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on August 17, 2017